science newsletter: Science News SciGuru.com

Δευτέρα 2 Σεπτεμβρίου 2013

Science News SciGuru.com

Common Blood Pressure Drug Reduces Aortic Enlargement in Marfan Syndrome
Treatment with the Anti-Diabetic Drug Alogliptin Does Not Increase Cardiovascular Risk in Patients with Acute Coronary Syndromes
PURE: Contrasting associations between risk factor burden, CVD incidence and mortality in high, middle and low income countries

Common Blood Pressure Drug Reduces Aortic Enlargement in Marfan Syndrome

Posted: 02 Sep 2013 06:08 AM PDT

A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome.

Results of the COMPARE (COzaar in Marfan PAtients Reduces aortic Enlargement) study reveal that patients treated with losartan (Cozaar) had a significantly reduced rate of aortic enlargement after 3 years compared to patients who did not receive the treatment.

Treatment with the Anti-Diabetic Drug Alogliptin Does Not Increase Cardiovascular Risk in Patients with Acute Coronary Syndromes

Posted: 02 Sep 2013 06:04 AM PDT

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial presented at the European Society of Cardiology Congress.

PURE: Contrasting associations between risk factor burden, CVD incidence and mortality in high, middle and low income countries

Posted: 02 Sep 2013 06:00 AM PDT

Despite being weighed down by more cardiovascular risk factors, people living in higher income countries are able to avoid many of the severe and even fatal consequences of cardiovascular disease (CVD) compared to their counterparts in lower income parts of the world.